Unicycive Therapeutics (UNCY) Competitors $0.68 -0.03 (-4.23%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends UNCY vs. LRMR, AMLX, LFCR, ITOS, BNTC, FHTX, ELDN, AVIR, RZLT, and URGNShould you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Larimar Therapeutics (LRMR), Amylyx Pharmaceuticals (AMLX), Lifecore Biomedical (LFCR), iTeos Therapeutics (ITOS), Benitec Biopharma (BNTC), Foghorn Therapeutics (FHTX), Eledon Pharmaceuticals (ELDN), Atea Pharmaceuticals (AVIR), Rezolute (RZLT), and UroGen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry. Unicycive Therapeutics vs. Larimar Therapeutics Amylyx Pharmaceuticals Lifecore Biomedical iTeos Therapeutics Benitec Biopharma Foghorn Therapeutics Eledon Pharmaceuticals Atea Pharmaceuticals Rezolute UroGen Pharma Larimar Therapeutics (NASDAQ:LRMR) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, community ranking, risk, institutional ownership and earnings. Is LRMR or UNCY more profitable? Unicycive Therapeutics' return on equity of 0.00% beat Larimar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Larimar TherapeuticsN/A -35.87% -32.37% Unicycive Therapeutics N/A N/A -29.88% Does the media prefer LRMR or UNCY? In the previous week, Larimar Therapeutics had 21 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 22 mentions for Larimar Therapeutics and 1 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.56 beat Larimar Therapeutics' score of -0.18 indicating that Unicycive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Unicycive Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of LRMR or UNCY? 91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 3.5% of Larimar Therapeutics shares are held by insiders. Comparatively, 24.1% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate LRMR or UNCY? Larimar Therapeutics currently has a consensus target price of $20.43, indicating a potential upside of 409.44%. Unicycive Therapeutics has a consensus target price of $5.13, indicating a potential upside of 653.68%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than Larimar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the MarketBeat Community believe in LRMR or UNCY? Larimar Therapeutics received 10 more outperform votes than Unicycive Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Unicycive Therapeutics an outperform vote while only 68.97% of users gave Larimar Therapeutics an outperform vote. CompanyUnderperformOutperformLarimar TherapeuticsOutperform Votes4068.97% Underperform Votes1831.03% Unicycive TherapeuticsOutperform Votes3075.00% Underperform Votes1025.00% Which has more risk & volatility, LRMR or UNCY? Larimar Therapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 2.36, suggesting that its stock price is 136% more volatile than the S&P 500. Which has stronger earnings & valuation, LRMR or UNCY? Unicycive Therapeutics has higher revenue and earnings than Larimar Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLarimar TherapeuticsN/AN/A-$36.95M-$1.15-3.49Unicycive Therapeutics$680K103.80-$30.54M-$0.97-0.70 SummaryUnicycive Therapeutics beats Larimar Therapeutics on 12 of the 16 factors compared between the two stocks. Ad Weiss RatingsBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.This could be his favorite coin. Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UNCY vs. The Competition Export to ExcelMetricUnicycive TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.58M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-0.7010.4289.5817.17Price / Sales103.80195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book-6.185.094.774.78Net Income-$30.54M$151.83M$120.15M$225.60M7 Day Performance-4.83%-2.13%-1.92%-1.23%1 Month Performance28.84%-3.10%11.47%3.36%1 Year Performance19.30%11.54%30.54%16.60% Unicycive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UNCYUnicycive Therapeutics3.3821 of 5 stars$0.68-4.2%$5.13+653.7%+18.3%$70.58M$680,000.00-0.709LRMRLarimar Therapeutics1.5678 of 5 stars$4.52-26.7%$20.43+352.0%+4.4%$288.42MN/A-3.5630Analyst RevisionNews CoveragePositive NewsGap DownHigh Trading VolumeAMLXAmylyx Pharmaceuticals4.2561 of 5 stars$4.17+1.2%$7.33+75.9%-70.7%$285.85M$196.49M-1.08200Short Interest ↓News CoveragePositive NewsLFCRLifecore Biomedical2.9037 of 5 stars$7.76+2.0%$10.00+28.9%+18.7%$285.78M$128.44M97.50690ITOSiTeos Therapeutics3.5018 of 5 stars$7.76+1.0%$25.25+225.4%-28.4%$283.50M$35M-2.4490Analyst ForecastBNTCBenitec Biopharma3.5922 of 5 stars$12.13+3.1%$24.43+101.4%+277.8%$281.66M$80,000.000.0020Analyst RevisionFHTXFoghorn Therapeutics2.882 of 5 stars$4.97-6.2%$16.00+221.9%-14.0%$276.30M$25.52M-2.63120Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeELDNEledon Pharmaceuticals2.9237 of 5 stars$4.50+2.7%$16.00+255.6%+196.6%$268.83MN/A-2.3310Positive NewsAVIRAtea Pharmaceuticals3.0689 of 5 stars$3.18+8.5%$6.88+116.4%+5.6%$268.59M$351.37M-1.5370High Trading VolumeRZLTRezolute3.1803 of 5 stars$4.62+0.7%$24.13+422.2%+387.8%$267.70MN/A-3.6140URGNUroGen Pharma3.8788 of 5 stars$11.41+0.5%$43.70+283.0%-28.4%$267.56M$82.71M-3.60200 Related Companies and Tools Related Companies Larimar Therapeutics Alternatives Amylyx Pharmaceuticals Alternatives Lifecore Biomedical Alternatives iTeos Therapeutics Alternatives Benitec Biopharma Alternatives Foghorn Therapeutics Alternatives Eledon Pharmaceuticals Alternatives Atea Pharmaceuticals Alternatives Rezolute Alternatives UroGen Pharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:UNCY) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UNCY Stock Alerts